KineMed Inc. (www.kinemed.com) announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE:PFE), for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways. Pfizer Inc. (NYSE:PFE), net profit margin is 81.20% and weekly performance is -0.07%. On last trading day company shares ended up $29.59. Analysts mean target price for the company is $34.45. Pfizer Inc. (NYSE:PFE), distance from 50-day simple moving average (SMA50) is -2..44%.
Merck & Co., Inc. (NYSE:MRK), announced about the first presentation of early data Investigational Anti-PD-1 Antibody Pembrolizumab (MK-3475). Merck & Co., Inc. (NYSE:MRK), fell 0.03% in last trading session and ended the day on $57.91. MRK, Gross Margin is 58.50% and its return on assets is 5.70%. Merck & Co., Inc. (NYSE:MRK), quarterly performance is 2.28%.
Chicago sued Johnson & Johnson (NYSE:JNJ), and four other drug companies for allegedly pushing consumer use of opioid painkillers, creating addicts and driving up its costs. Johnson & Johnson (NYSE:JNJ), shares moved up 0.28% in last trading session and was closed at $102.46, while trading in range of $101.84 – 102.60. Johnson & Johnson (NYSE:JNJ), year to date (YTD) performance is 13.45%.
Bristol-Myers Squibb Co (NYSE:BMY), said that phase 3 Study evaluating Yervoy (Ipilimumab) for Melanoma in an Adjuvant Setting met primary endpoint of recurrence-free survival. Bristol-Myers Squibb Co (NYSE:BMY), ended the last trading day at $48.98. Company weekly volatility is calculated as 1.75% and price to cash ratio as 11.50. Bristol-Myers Squibb Co (NYSE:BMY), showed a negative weekly performance of 0.18%.
AstraZeneca plc (ADR) (NYSE:AZN)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Credit Suisse in a research note issued to investors on Wednesday. They currently have a GBX 4,800 ($80.47) price target on the stock. Credit Suisse’s price objective would suggest a potential upside of 10.37% from the company’s current price. AstraZeneca plc (ADR) (NYSE:AZN), net profit margin is 8.00% and weekly performance is 0.99%. On last trading day company shares ended up $72.76. Analysts mean target price for the company is $72.53. AstraZeneca plc (ADR) (NYSE:AZN), distance from 50-day simple moving average (SMA50) is 3.08%.